A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study - Concepedia

Concepedia

Publication | Open Access

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

DOI Full Paper Access

601

Citations

19

References

2013

Year

Won Park, Paweł Hrycaj, Volodymyr Kovalenko, Grygorii Lysenko, Pedro C. Miranda, Helēna Mikažāne, Sergio Gutiérrez‐Ureña, Mie Jin Lim, Yeon-Ah Lee, Sang Joon Lee,

Annals of the Rheumatic Diseases

Abstract

The PK profiles of CT-P13 and INX were equivalent in patients with active AS. CT-P13 was well tolerated, with an efficacy and safety profile comparable to that of INX up to week 30.

References

	Year	Citations

Page 1